Loading
A phase 1 trial of CFI-400945 run by University Health Network, Toronto, completed.
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS is a phase 1 interventional study registered as NCT03187288 by University Health Network, Toronto, with 13 participants enrolled, started 2018-05-25. Conditions recorded: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer and Refractory Cancer. Interventions recorded: CFI-400945 Fumarate.
Shares CFI-400945, Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/